You have 9 free searches left this month | for more free features.

obinutuzumab

Showing 1 - 25 of 166

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Chronic Lymphocytic Leukemia Trial (Acalabrutinib, Obinutuzumab)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • (no location specified)
Jul 10, 2023

Follicular Lymphoma, Tumor Trial in Houston (Obinutuzumab, CC-99282)

Not yet recruiting
  • Follicular Lymphoma
  • Tumor
  • Houston, Texas
    M D Anderson Cancer Center
Oct 30, 2023

Obinutuzumab-based Therapy for Previously Untreated FL

Recruiting
  • Follicular Lymphoma
  • Obinutuzumab
  • +6 more
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
Jun 3, 2023

CLL Trial (Sonrotoclax, Zanubrutinib, Venetoclax)

Not yet recruiting
  • CLL
  • (no location specified)
Oct 3, 2023

Large B-cell Lymphoma Trial (Glofitamab, Polatuzumab vedotin, Obinutuzumab)

Not yet recruiting
  • Large B-cell Lymphoma
  • (no location specified)
Oct 3, 2023

Mantle Cell Lymphoma, Non-hodgkin Lymphoma, Non Hodgkin Lymphoma Trial in Madison (Bendamustine, Obinutuzumab)

Recruiting
  • Mantle Cell Lymphoma
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
Sep 13, 2022

Urothelial Carcinoma Trial in New York (Naptumomab Estafenatox, Pembrolizumab, Obinutuzumab)

Not yet recruiting
  • Urothelial Carcinoma
  • Naptumomab Estafenatox
  • +2 more
  • New York, New York
    Weill Cornell Medicine/NewYork-Presbyterian Hospital
May 30, 2023

Childhood Nephrotic Syndrome Trial (Obinutuzumab, MMF, Prednisone)

Not yet recruiting
  • Childhood Nephrotic Syndrome
  • Obinutuzumab
  • +5 more
  • (no location specified)
Nov 23, 2022

Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)

Recruiting
  • Follicular Lymphoma
  • +4 more
  • Obinutuzumab
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

CCND1 Positive, Mantle Cell Lymphoma, t(11;14) Positive Trial in Atlanta, Johns Creek (Bendamustine, Obinutuzumab, Venetoclax)

Active, not recruiting
  • CCND1 Positive
  • +2 more
  • Atlanta, Georgia
  • +2 more
Nov 2, 2022

Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma Trial in Boston (Obinutuzumab, Glofitamab)

Not yet recruiting
  • Follicular Lymphoma
  • +2 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Mar 13, 2023

Chronic Lymphocytic Leukemia (CLL) Trial in United States (Venetoclax, Obinutuzumab, Acalabrutinib)

Active, not recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Stamford, Connecticut
  • +4 more
Dec 2, 2022

Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL) Trial (parsaclisib, rituximab, obinutuzumab)

Withdrawn
  • Follicular Lymphoma ( FL)
  • Marginal Zone Lymphoma (MZL)
  • (no location specified)
Jul 14, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Columbus (Acalabrutinib, Obinutuzumab, Venetoclax)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 2, 2022

Leukemia Trial in Houston (Pirtobrutinib, Obinutuzumab, Venetoclax)

Not yet recruiting
  • Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Sep 7, 2022

Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,

Completed
  • Grade 3a Follicular Lymphoma
  • +9 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 31, 2023

Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the National Cancer Institute (NCI) (Venetoclax, Ibrutinib, Prednisone)

Recruiting
  • Lymphoma
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 20, 2022

Chronic Lymphocytic Leukemia Trial in Portland (drug, procedure, biological, other)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Portland, Oregon
    OHSU Knight Cancer Institute
Jul 12, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Houston (Acalabrutinib, Obinutuzumab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jul 14, 2022

Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma Trial in

Recruiting
  • Ann Arbor Stage II Follicular Lymphoma
  • +5 more
  • Fresno, California
  • +2 more
Jan 24, 2023

Leukemia, Lymphocytic, Chronic Trial in Germany (ibrutinib, obinutuzumab, venetoclax)

Completed
  • Leukemia, Lymphocytic, Chronic
  • Dresden, Germany
  • +10 more
Jan 13, 2023

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Trial in Suzhou (Obinutuzumab, Zanubrutinib, Lenalidomide)

Enrolling by invitation
  • Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
  • Obinutuzumab
  • +6 more
  • Suzhou, Jiangsu, China
    the First Affiliated Hospital of Soochow University
Mar 22, 2023

DLBCL Trial (maplirpacept (PF-07901801), Glofitamab, Obinutuzumab)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • maplirpacept (PF-07901801)
  • +2 more
  • (no location specified)
May 30, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Scottsdale, Jacksonville, Rochester (drug, other, biological)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Scottsdale, Arizona
  • +2 more
Jan 5, 2023

Granulomatosis With Polyangiitis, Microscopic Polyangiitis, ANCA Associated Vasculitis Trial in Boston, Rochester, Philadelphia

Not yet recruiting
  • Granulomatosis With Polyangiitis
  • +2 more
  • Boston, Massachusetts
  • +2 more
Dec 29, 2022